A Point Biopharma Global cancer therapy key to a $1.4 billion Eli Lilly M&A deal has met the main goal of its pivotal clinical trial in prostate cancer. But the results raise questions about how well ...

Why would any healthy person, newly diagnosed with cancer, elect not to undergo curative treatment? Newly diagnosed prostate cancer patients presented with the option of active surveillance often ask ...

NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., a global leader ...

There are four broad classes of context-specific biomarkers that may have clinical utility in oncology. 1 The first relates to prognostic markers, which aid in defining disease prognosis in a ...

J Natl Compr Canc Netw. 2007;5(7):693-698. The primary concern with using PSADT as a trigger for curative intervention is that it may act as a marker of aggressive disease that has already progressed ...